iLiAD Biotechnologies, Inserm And Inserm Transfert SA, And Institut Pasteur de Lille Enter Scientific Collaboration And Worldwide License Agreements For Vaccine Technology
1/9/2014 8:19:35 AM
NEW YORK & PARIS & LILLE, France--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), the French National Institute of Health and Medical Research (Inserm) subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille (IPL) today announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore1 and National University of Ireland Maynooth2.
Help employers find you! Check out all the jobs and post your resume.
comments powered by